Cullinan Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $42,123 | $41,459 |
| General and administrative | 11,574 | 13,537 |
| Total operating expenses | 53,697 | 54,996 |
| Loss from operations | (53,697) | (54,996) |
| Other income (expense): | ||
| Interest income | 4,098 | 6,580 |
| Other expense, net | (62) | (85) |
| Net loss | $(49,661) | $(48,501) |
| Comprehensive income (loss): | ||
| Net loss | $(49,661) | $(48,501) |
| Unrealized gain (loss) on investments | (893) | 638 |
| Comprehensive loss | $(50,554) | $(47,863) |
| Basic and diluted net loss per share: | ||
| Common stock | $(0.75) | $(0.74) |
| Preferred stock | $(7.52) | $(7.42) |
| Weighted-average shares used in computing basic and diluted net loss per share: | ||
| Common stock | 60,462 | 58,905 |
| Preferred stock | 555 | 648 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.